Anti‐MUC1 aptamer: A potential opportunity for cancer treatment

Nabavinia, Maryam Sadat; Gholoobi, Aida; Charbgoo, Fahimeh; Nabavinia, Mahboubeh; Ramezani, Mohammad; Abnous, Khalil

doi:10.1002/med.21462

Cited by 113 publications

(76 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other molecular targets ought to be mentioned: interleukin receptors expressed, particularly, in some types of gliomas [205]; mesothelin which is involved in cell adhesion and is highly expressed on mesothelioma cells and in a number of adenocarcinomas [206,207]; prostate-specific membrane antigen PSMA [208,209]; plasma membrane proteoglycans, for example the mucin (MUC-1) overexpressed in carcinomas [210,211]. The altered glycosylation profile of the tumor cells surface makes them possible to be recognized by lectins [212].…”

Section: Active Targetingmentioning

confidence: 99%

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Kutova

Guryev

Соколова

et al. 2019

Cancers

View full text Add to dashboard Cite

Malignant tumors are characterized by structural and molecular peculiarities providing a possibility to directionally deliver antitumor drugs with minimal impact on healthy tissues and reduced side effects. Newly formed blood vessels in malignant lesions exhibit chaotic growth, disordered structure, irregular shape and diameter, protrusions, and blind ends, resulting in immature vasculature; the newly formed lymphatic vessels also have aberrant structure. Structural features of the tumor vasculature determine relatively easy penetration of large molecules as well as nanometer-sized particles through a blood–tissue barrier and their accumulation in a tumor tissue. Also, malignant cells have altered molecular profile due to significant changes in tumor cell metabolism at every level from the genome to metabolome. Recently, the tumor interaction with cells of immune system becomes the focus of particular attention, that among others findings resulted in extensive study of cells with preferential tropism to tumor. In this review we summarize the information on the diversity of currently existing approaches to targeted drug delivery to tumor, including (i) passive targeting based on the specific features of tumor vasculature, (ii) active targeting which implies a specific binding of the antitumor agent with its molecular target, and (iii) cell-mediated tumor targeting.

show abstract

Section: Active Targetingmentioning

confidence: 99%

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Kutova

Guryev

Соколова

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Several high affinity aptamers have been isolated against MUC1: in particular, most of them have been selected against the exposed peptide backbone, named variable number tandem repeats (VNTR) peptide, containing highly immunogenic epitopes [ 187 ], or against the Tn (GalNAc) and T (Galβ1-3GalNAc) antigens O -linked to the peptide tandem repeat (for a detailed review, see reference [ 188 ]). Many of these aptamers are efficiently and specifically internalized through receptor-mediated endocytosis by epithelial cancer cells and can be used as delivery vehicles to specifically direct pro-drug cargoes, e.g., in photodynamic therapy (PDT) [ 189 ], or other cytotoxic agents (doxorubicin, paclitaxel, epirubicin, specific siRNA) [ 190 , 191 , 192 ] into cells to visualize but, above all, kill them.…”

Section: Aptamer-based Fluorescent Systems For the Specific Recognmentioning

confidence: 99%

“…To date, among the various aptamers identified against MUC1 [ 188 ], only the aptamer selected by Ferreira et al has been used in fluorescence sensing strategies [ 187 ].…”

Section: Aptamer-based Fluorescent Systems For the Specific Recognmentioning

confidence: 99%

Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics

Musumeci

Platella

Riccardi

et al. 2017

Cancers

View full text Add to dashboard Cite

Among the various advantages of aptamers over antibodies, remarkable is their ability to tolerate a large number of chemical modifications within their backbone or at the termini without losing significant activity. Indeed, aptamers can be easily equipped with a wide variety of reporter groups or coupled to different carriers, nanoparticles, or other biomolecules, thus producing valuable molecular recognition tools effective for diagnostic and therapeutic purposes. This review reports an updated overview on fluorescent DNA aptamers, designed to recognize significant cancer biomarkers both in soluble or membrane-bound form. In many examples, the aptamer secondary structure switches induced by target recognition are suitably translated in a detectable fluorescent signal using either fluorescently-labelled or label-free aptamers. The fluorescence emission changes, producing an enhancement (“signal-on”) or a quenching (“signal-off”) effect, directly reflect the extent of the binding, thereby allowing for quantitative determination of the target in bioanalytical assays. Furthermore, several aptamers conjugated to fluorescent probes proved to be effective for applications in tumour diagnosis and intraoperative surgery, producing tumour-type specific, non-invasive in vivo imaging tools for cancer pre- and post-treatment assessment.

show abstract

“…Nucleic acid aptamers against proteins have attracted tremendous attention since they were discovered, the interactions between proteins and aptamers are one of hotspots of biochemistry, molecular biology, bioinformatics and biophysics [1]. Due to the high affinity and specificity of nucleic acid aptamers, protein-aptamer interactions have become more significant for targeted drug therapy of complex diseases and have a perform a variety of functions [2][3][4][5]. Aptamers are typically identified in vitro from random libraries of DNA or RNA molecules using an iterative process of Systematic Evolution of Ligands by Exponential Enrichment (SELEX) [6], which consists of several repeated rounds of binding, partition and amplification.…”

Section: Introductionmentioning

confidence: 99%

PPAI: a web server for predicting protein-aptamer interactions

et al. 2020

BMC Bioinformatics

View full text Add to dashboard Cite

Background: The interactions between proteins and aptamers are prevalent in organisms and play an important role in various life activities. Thanks to the rapid accumulation of protein-aptamer interaction data, it is necessary and feasible to construct an accurate and effective computational model to predict aptamers binding to certain interested proteins and protein-aptamer interactions, which is beneficial for understanding mechanisms of protein-aptamer interactions and improving aptamer-based therapies. Results: In this study, a novel web server named PPAI is developed to predict aptamers and protein-aptamer interactions with key sequence features of proteins/ aptamers and a machine learning framework integrated adaboost and random forest. A new method for extracting several key sequence features of both proteins and aptamers is presented, where the features for proteins are extracted from amino acid composition, pseudo-amino acid composition, grouped amino acid composition, C/T/D composition and sequence-order-coupling number, while the features for aptamers are extracted from nucleotide composition, pseudo-nucleotide composition (PseKNC) and normalized Moreau-Broto autocorrelation coefficient. On the basis of these feature sets and balanced the samples with SMOTE algorithm, we validate the performance of PPAI by the independent test set. The results demonstrate that the Area Under Curve (AUC) is 0.907 for prediction of aptamer, while the AUC reaches 0.871 for prediction of protein-aptamer interactions. Conclusion: These results indicate that PPAI can query aptamers and proteins, predict aptamers and predict protein-aptamer interactions in batch mode precisely and efficiently, which would be a novel bioinformatics tool for the research of protein-aptamer interactions. PPAI web-server is freely available at http://39.96.85.9/ PPAI.

show abstract

Anti‐MUC1 aptamer: A potential opportunity for cancer treatment

Cited by 113 publications

References 84 publications

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency

Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics

PPAI: a web server for predicting protein-aptamer interactions

Contact Info

Product

Resources

About